AVBP - Company ID 0001868279
The table below shows ArriVent BioPharma, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $154.68M | $62.10M | $112.67M | $112.77M | $49.87M | $282.86M |
| Short-term investments | $218.44M | $264.28M | $187.59M | $122.92M | $126.21M | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $394.17M |
| $348.70M |
| $321.22M |
| $250.15M |
| $185.78M |
| $292.40M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $394.72M | $349.30M | $326.56M | $269.51M | $215.50M | $292.71M |
| Accounts payable | $2.22M | $8.73M | $5.93M | $4.06M | $4.36M | $4.65M |
| Total current liabilities | $27.84M | $25.00M | $21.56M | $19.64M | $12.95M | $15.16M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $27.88M | $25.32M | $21.56M | $19.64M | $12.95M | $15.22M |
| Retained earnings | -$497.85M | -$447.96M | -$369.10M | -$334.12M | -$302.72M | -$217.70M |
| Total equity | $366.84M | $323.98M | $305.00M | $249.87M | $202.54M | $277.49M |